Capital International Inc. CA Sells 16,086 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Capital International Inc. CA decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 21.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 59,552 shares of the biopharmaceutical company’s stock after selling 16,086 shares during the quarter. Capital International Inc. CA’s holdings in Alnylam Pharmaceuticals were worth $23,681,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 50.6% during the 4th quarter. Los Angeles Capital Management LLC now owns 240,052 shares of the biopharmaceutical company’s stock worth $95,457,000 after purchasing an additional 80,658 shares during the last quarter. Cookson Peirce & Co. Inc. raised its holdings in Alnylam Pharmaceuticals by 48.3% during the 4th quarter. Cookson Peirce & Co. Inc. now owns 811 shares of the biopharmaceutical company’s stock worth $322,000 after purchasing an additional 264 shares during the last quarter. Havemeyer Place LP bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $118,000. 111 Capital bought a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $577,000. Finally, Vestcor Inc raised its holdings in Alnylam Pharmaceuticals by 39.8% during the 4th quarter. Vestcor Inc now owns 3,533 shares of the biopharmaceutical company’s stock worth $1,405,000 after purchasing an additional 1,006 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $303.05 on Monday. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The company has a market capitalization of $40.46 billion, a price-to-earnings ratio of 82.80 and a beta of 0.29. The firm’s fifty day moving average price is $307.66 and its two-hundred day moving average price is $348.58. Alnylam Pharmaceuticals, Inc. has a 1 year low of $283.10 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s revenue for the quarter was up 96.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.44) EPS. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 7.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on ALNY. Needham & Company LLC lowered their price target on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a report on Friday, May 1st. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $463.13.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider directly owned 9,443 shares in the company, valued at $3,120,156.06. This represents a 19.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 7,740 shares of company stock worth $2,420,214 over the last ninety days. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.